A study to learn more about treating malignant mesothelioma - can we improve quality of life?

A multicentre non-blinded

randomised controlled trial to

assess the impact of Regular Early

SPEcialist symptom Control

Treatment on quality of life in

malignant Mesothelioma - “RESPECT-Meso”

A multi-centre non-blinded randomised controlled trial to assess the impact of regular early specialist palliative care treatment on quality of life on malignant mesothelioma

What was this study about?

This study examined if involving palliative care specialists early in the treatment of mesothelioma improves the quality of life and wellbeing of patients.  We are also interested in how this specialist treatment might affect the wellbeing of family or close friends, closest to patients with this illness.

RESPECT-Meso recruitment complete and results are

expected late 2017

We are delighted to confirm that the Respect-Meso study completed all follow up in late May 2017 and preliminary analysis of the results has begun. Early results are expected to be announced in late 2017 – watch this space for news and updates as they come available. We are indebted and grateful to the patients and carers who have supported the study and to the numerous healthcare professionals from the 24 hospitals, research and trials units that have assisted us with this study.

What is

mesothelioma?

Malignant mesothelioma is a rare cancer of the lining of the chest commonly caused by exposure to asbestos. This exposure may have occurred up to forty years earlier. Mesothelioma usually causes symptoms like breathlessness, loss of weight and chest pain, but it can affect people in different ways. There is no cure for mesothelioma. This study seeks to learn how best we can support patients with mesothelioma and their families.